No association between BDNF Val66Met polymorphism and treatment response in obsessive-compulsive disorder in the Japanese population

Aim: Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, and it promotes the development and function of dopaminergic and serotonergic neurons. The Met allele of the BDNF Val66Met polymorphism is associated with a decrease in activity-dependent secretion of BDNF compared with the Val allele, and a number of studies have provided evidence for the association between this polymorphism and obsessive-compulsive disorder (OCD). The purpose of this study was to investigate whether this functional variant of the BDNF gene is associated with OCD and treatment response in patients with OCD in the Japanese population.

Methods: We first performed a case–control association study between the BDNF Val66Met polymorphism and OCD (175 cases and 2,027 controls). Then, we examined an association between this polymorphism and treatment response in 96 patients with OCD.

Results: We found no significant association between the Met allele and OCD risk or between the Met allele and treatment responses to selective serotonin reuptake inhibitors or serotonin reuptake inhibitor with an atypical antipsychotic (P>0.05).

Conclusion: Our results suggest that the BDNF Val66Met polymorphism may not be associated as a risk factor for developing OCD or with therapeutic response in patients with OCD in the Japanese population.

Keywords: obsessive-compulsive disorder, BDNF, treatment response, association study, SSRI, atypical antipsychotic

Introduction

Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder with a prevalence of ~2%, and it is characterized by repetitive, persistent, intrusive thoughts and repetitive, compulsive behaviors.1 Serotonin reuptake inhibitors (SRIs) and antipsychotics are used as pharmacological treatments for OCD,2 suggesting that changes of serotonergic and dopaminergic neurotransmissions may be related to OCD.

Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, which is known to regulate many aspects of neural circuit development and function, including cell proliferation and differentiation, axon and dendrite growth, synaptogenesis, and synaptic function and plasticity.2,3 Substantial evidence suggests that BDNF promotes the development and function of dopaminergic and serotonergic neurons.6,7 Several studies have demonstrated that patients with OCD had significantly decreased plasma and serum BDNF levels compared with controls,8-12 and the administration of selective SRIs (SSRIs) and atypical antipsychotics enhances BDNF gene expression.6,13

**Correspondence:** Shusuke Numata
Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Laboratory of Aging, Behavior and Cognition, Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Academic Support Office for Students with Special Needs, Tokushima University, Tokushima, Japan

Tel +81 88 633 7130
Fax +81 88 633 7131
Email shu-numata@umin.ac.jp
The **BDNF Val66Met** polymorphism (rs6265) is a functional polymorphism, which affects intracellular processing and secretion of BDNF, with the Met allele being associated with a decrease in activity-dependent secretion of BDNF compared with the Val allele. This polymorphism has been extensively investigated in patients with OCD, and a number of studies have provided evidence for association between this polymorphism and OCD. For example, one family-based association study and four case–control studies have demonstrated that the **BDNF Val66Met** polymorphism might be genetically involved in the etiology of OCD, although a recent meta-analysis of genetic association studies failed to support these findings. In addition, several studies have demonstrated that the **BDNF Val66Met** polymorphism was associated with clinical characteristics of OCD, such as symptom severity, age of onset, family history, poor executive functions, and impairments in decision making. Furthermore, the **BDNF Val66Met** polymorphism was associated with treatment response to exposure-based cognitive-behavior therapy in patients with OCD, and a **BDNF** haplotype, including the **BDNF Val66Met** polymorphism, was associated with treatment response to antidepressants in patients with OCD.

In this study, we hypothesized that the **BDNF Val66Met** polymorphism would be involved in the pathophysiology as well as treatment response of OCD in the Japanese population. We first performed a case–control association study to determine whether the **BDNF Val66Met** polymorphism was genetically implicated in patients with OCD, and a **BDNF** haplotype, including the **BDNF Val66Met** polymorphism, was associated with treatment response to antidepressants in patients with OCD.

Subjects and methods

### Subjects

A total of 175 patients with OCD (82 males and 93 females, mean age: 33.7±10.9 years) were recruited from the Tokushima University Hospital and Yagoto Hospital in Japan in the South Island of Japan (Shikoku) and Yagoto Hospital at Middle West in the Mainland of Japan. All patients were of Japanese descent. The diagnosis of OCD was made according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria by at least two expert psychiatrists on the basis of extensive clinical interviews and a review of medical records. Patients comorbid with other axis I disorders were excluded. Among the 175 patients with OCD, 96 patients participated in the present pharmacogenetic study. These patients were divided into three groups according to the treatment response evaluated by the Yale Brown Obsessive-Compulsive Scale (Y-BOCS) as follows: SSRI (fluvoxamine, paroxetine, sertraline, or escitalopram) responders as group A (N=56); SSRI with an atypical antipsychotic augmentation (risperidone, olanzapine, quetiapine, perospirone, or aripiprazole) responders as group B (N=23); and nonresponders to either SSRI or SSRI with an atypical antipsychotic augmentation as group C (N=17). The treatment responders were defined as patients with a reduction in Y-BOCS >35%. They were treated in a naturalistic clinical course, and the mean follow-up duration was 12.9±8.2 months. Only the patients who had no response to SSRI were treated by adding an atypical antipsychotic drug (group B plus C). There were no significant differences among the three groups in sex, age, onset age, or duration of illness, while significant differences were found in Y-BOCS scores at baseline and at the end of the treatment (Table 1). Most of these samples were used in our previous study. The control group comprised

### Table 1: Treatment response group and clinical symptoms of patients with obsessive-compulsive disorder

<table>
<thead>
<tr>
<th></th>
<th>Group A (N=56)</th>
<th>Group B (N=23)</th>
<th>Group C (N=17)</th>
<th>All patient groups</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>26 (46.4)</td>
<td>13 (56.5)</td>
<td>9 (52.9)</td>
<td>48 (50)</td>
<td>0.69</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>30 (53.6)</td>
<td>10 (43.5)</td>
<td>8 (47.1)</td>
<td>48 (50)</td>
<td></td>
</tr>
<tr>
<td><strong>Age, mean (SD)</strong></td>
<td>32.86 (12.79)</td>
<td>30.39 (11.07)</td>
<td>28.53 (9.77)</td>
<td>31.5 (11.9)</td>
<td>0.38</td>
</tr>
<tr>
<td><strong>Onset age, mean (SD)</strong></td>
<td>24.75 (10.71)</td>
<td>22.74 (12.05)</td>
<td>18.35 (10.94)</td>
<td>23.1 (11.2)</td>
<td>0.12</td>
</tr>
<tr>
<td><strong>Duration of illness, mean (SD)</strong></td>
<td>8.11 (9.14)</td>
<td>7.65 (6.29)</td>
<td>10.18 (10.19)</td>
<td>8.4 (8.6)</td>
<td>0.63</td>
</tr>
<tr>
<td><strong>Y-BOCS score</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline, mean (SD)</td>
<td>23.27 (5.04)</td>
<td>25.57 (4.51)</td>
<td>28.41 (4.43)</td>
<td>24.7 (5.1)</td>
<td>0.001</td>
</tr>
<tr>
<td>After treatment, mean (SD)</td>
<td>8.20 (3.86)</td>
<td>11.43 (2.97)</td>
<td>25.33 (4.64)</td>
<td>12.0 (7.4)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

**Notes:** P-values are calculated by χ² and ANOVA. Duration of illness measured as the length from the onset of obsessive-compulsive disorder to start of the treatment in the Tokushima University Hospital. Group A, responders to SSRI; group B, responders to SSRI with an atypical antipsychotic; group C, nonresponders to SSRI with an atypical antipsychotic.

**Abbreviations:** ANOVA, analysis of variance; SSRI, selective serotonin reuptake inhibitor; Y-BOCS, Yale Brown Obsessive-Compulsive Scale; SD: standard deviation.
2,027 volunteers (855 males and 1,172 females; mean age: 38.7±13.3 years) recruited from hospital staff, students, and company employees who were documented to be free from psychiatric problems with no past history of mental illness. All of them were of Japanese descent. Details can be seen in our previous paper.27 The institutional ethics committee of the University of Tokushima Graduate School approved the current study and all subjects signed written, informed consent forms.

Genotyping
We genotyped the BDNF Val66Met polymorphism (rs6265) by using a commercially available TaqMan probe with the Applied Biosystems 7500 Fast Real Time PCR System and followed the protocol recommended by the manufacturer (Thermo Fisher Scientific, Waltham, MA, USA).

Statistical methods
The association between rs6265 and OCD and the association between rs6265 and treatment response in patients with OCD were examined using logistic regression under a log-additive model. Odds ratio (OR), 95% confidence intervals (CIs), and P-value were calculated by using R Version 3.1.2. Power calculation was performed using the G*Power 3.1.28

Results
Association between rs6265 and OCD
The genotype and allele distributions of rs6265 are shown in Table 2. The genotypic distribution of rs6265 did not deviate significantly from the Hardy–Weinberg equilibrium in the patient group or in the control group (P>0.05). We revealed no significant effect of the Met allele on the OCD risk in our sample set (per-allele OR, 1.05; 95% CI, 0.84–1.31; P=0.68).

Association between rs6265 and the treatment response in patients with OCD
When we compared group A with group B plus C, we did not find a significant association between rs6265 and the treatment response to SSRI (per-allele OR, 1.43; 95% CI, 0.78–2.59; P=0.24). When we compared group B with group C, we did not find a significant association between rs6265 and the treatment response to SSRI with an antipsychotic medication (per-allele OR, 1.28; 95% CI, 0.54–3.03; P=0.57). When we compared group A plus B with group C, we did not find a significant association between rs6265 and the treatment response to SSRI or SSRI with an antipsychotic medication (per-allele OR, 1.59; 95% CI, 0.718–3.53; P=0.25).

The power of our sample size for the treatment response had 0.27 (group A vs group B plus C), 0.14 (group B vs group C), and 0.15 (group A plus B vs group C), respectively, for detecting a significant association (α=0.05) when we applied an OR of 1.4 in the power calculations.

Discussion
First, we found no significant effect on the Met allele of the BDNF Val66Met polymorphism on the OCD risk. This is the first association study between the BDNF Val66Met polymorphism and OCD conducted on a Japanese population. Our finding is consistent with the results of two meta-analyses of previous association studies21,29 and with the results of two genome-wide association studies.30,31 Zai et al conducted a meta-analysis of 13 genetic association studies (five family-based association studies and eight case–control studies, which included Caucasian, Turk, Mexican, and South African Afrikaner cohorts), and they found no association between the BDNF Val66Met polymorphism and OCD (allele OR, 1.09; 95% CI, 0.99–1.21; P=0.09).21 Matheisen et al conducted a genome-wide association studies (N=5,061), and they did not find the BDNF Val66Met polymorphism among the top 33 single-nucleotide polymorphisms (SNPs) with P<1×10−5.30 However, caution must be exercised, because the sample size of each association study, including our study, was small, and the allele frequency of this polymorphism is dependent on ethnic background.32

Second, we demonstrated that the BDNF Val66Met polymorphism was not associated with treatment responses to SSRI in patients with OCD. This result is consistent with the result of a previous pharmacogenetic association study of BDNF variants in patients with OCD25 and the result of a genome-wide association study of treatment response in patients with OCD.33 Real et al compared a group of good responders with a group of poor responders to SRIs (fluoxetine, fluvoxamine, or clomipramine) in patients

### Table 2 Genotype and allele distributions in subjects with obsessive-compulsive disorder and control subjects

<table>
<thead>
<tr>
<th>Subject group</th>
<th>Subjects (n)</th>
<th>Val/Val (n)</th>
<th>Val/Met (n)</th>
<th>Met/Met (n)</th>
<th>Val (n)</th>
<th>Met (n)</th>
<th>HWE</th>
<th>OR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>OCD</td>
<td>175</td>
<td>59</td>
<td>83</td>
<td>33</td>
<td>201</td>
<td>149</td>
<td>0.69</td>
<td>1.05 (0.84–1.31)</td>
<td>0.68</td>
</tr>
<tr>
<td>Control</td>
<td>2,027</td>
<td>686</td>
<td>1,002</td>
<td>339</td>
<td>2,374</td>
<td>1,680</td>
<td>0.40</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** CI, confidence interval; HWE, Hardy–Weinberg equilibrium; Met, methionine; OCD, obsessive-compulsive disorder; OR, odds ratio; Val, valine.
with OCD for 12 weeks (N=123), and they did not find a significant association between the BDNF Val66Met polymorphism and clinical response, although they did reveal significant differences between nonresponders and responders in the haplotype-based analysis of four SNPs (rs1103009, rs10501087, rs6265, and rs1491850).\(^3\)\(^5\) Qin et al conducted a genome-wide association analysis of SRI response in 804 patients with OCD, and they could not find the BDNF Val66Met polymorphism among the top 42 SNPs with \(P<1\times10^{-4}\).\(^3\)\(^3\) However, the follow-up periods (12.9 months vs 12 weeks vs lack of detailed information), SRI medications, and definitions of treatment response (based on Y-BOCS vs based on self-report) differed among these three studies.

Finally, we demonstrated that the BDNF Val66Met polymorphism was not associated with treatment response to SSRI with an atypical antipsychotic in patients with OCD. This is the first pharmacogenetic study to evaluate the effect of BDNF Val66Met polymorphism on treatment response to SSRI with an atypical antipsychotic in patients with OCD. However, our sample size was small, and our patients were treated with a variety of SSRI and atypical antipsychotics. Further replication studies using larger samples with unified medications will be needed.

**Conclusion**

In conclusion, the BDNF Val66Met polymorphism may not be associated as a risk factor for developing OCD or the therapeutic responses to SSRI or to SSRI with an atypical antipsychotic, in patients with OCD in the Japanese population.

**Acknowledgments**

The authors would like to thank all the volunteers who understood our study purpose and participated in this study, and the physicians who helped us to collect clinical data and blood samples at the mental hospitals. The authors would also like to thank Mrs Akemi Okada for her technical assistance. This work was supported by Grant-in-Aid for Scientific Research (C) (no 26245678).

**Author contributions**

Drs Numata and Ohmori designed the study and acquired the data. Drs Nakaaki, Kinoshita, Sumitani, Watanabe, and Umehara acquired the data, and Dr Umehara analyzed the data. Dr Umehara wrote the first draft of the manuscript. All authors contributed toward data analysis, drafting and critically revising the paper, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


